Tonix Pharmaceuticals Secures Coverage for Tonmya with GPO Agreement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy TNXP?
Source: seekingalpha
- Agreement Reached: Tonix Pharmaceuticals has entered into an agreement with a group purchasing organization to secure commercial payer coverage for its non-opioid pain therapy, Tonmya, which is expected to cover approximately 35 million U.S. commercial lives, accounting for about one-fifth of the total U.S. commercial lives.
- Market Potential Unveiled: The agreement took effect on May 1, marking Tonix's first partnership in managed care, with CEO Seth Lederman expressing optimism about this collaboration and looking forward to expanding coverage across commercial and government channels.
- Medicare Coverage Status: Tonmya, a sublingual tablet formulation, is currently covered under Medicare in 38 states, involving nearly 55 million Medicaid members, which constitutes 73% of the approximately 75 million members of the joint federal and state healthcare plan, indicating its broad acceptance in the healthcare market.
- Expansion Discussions Ongoing: Tonix is currently in discussions with Medicare and Medicaid to widen the coverage for Tonmya, which is expected to support future revenue growth for the company and enhance its competitive position in the pain management market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TNXP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TNXP
Wall Street analysts forecast TNXP stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 13.620
Low
65.00
Averages
67.50
High
70.00
Current: 13.620
Low
65.00
Averages
67.50
High
70.00
About TNXP
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing and commercializing therapeutics to treat and vaccines to prevent, disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801, TNX-1800, TNX-4200, and TNX-1700. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Tonmya Receives FDA Approval, New Option for Fibromyalgia Treatment
- FDA Approval Milestone: Tonmya has become the first FDA-approved treatment for fibromyalgia in over 15 years, representing a significant advancement in non-opioid therapies for chronic pain management, which is expected to enhance patient quality of life.
- Market Access Expansion: The new agreement with a major purchasing organization broadens Tonmya's coverage to approximately 35 million commercially insured patients in the U.S., significantly increasing the drug's market accessibility and likely driving revenue growth for the company.
- Patient Support Commitment: Tonix is dedicated to improving patient access to Tonmya by engaging with commercial payers and offering a patient support program, addressing the dissatisfaction experienced by 85% of patients with first-line treatments due to efficacy and tolerability issues, thereby enhancing patient satisfaction.
- Future Research Initiatives: Tonix is also advancing clinical trials for TNX-4800, with plans to have drug supplies ready by 2027, which is expected to provide new treatment options for Lyme disease prevention, further expanding the company's product portfolio.
See More
Tonix Pharmaceuticals Secures Coverage for Tonmya with GPO Agreement
- Agreement Reached: Tonix Pharmaceuticals has entered into an agreement with a group purchasing organization to secure commercial payer coverage for its non-opioid pain therapy, Tonmya, which is expected to cover approximately 35 million U.S. commercial lives, accounting for about one-fifth of the total U.S. commercial lives.
- Market Potential Unveiled: The agreement took effect on May 1, marking Tonix's first partnership in managed care, with CEO Seth Lederman expressing optimism about this collaboration and looking forward to expanding coverage across commercial and government channels.
- Medicare Coverage Status: Tonmya, a sublingual tablet formulation, is currently covered under Medicare in 38 states, involving nearly 55 million Medicaid members, which constitutes 73% of the approximately 75 million members of the joint federal and state healthcare plan, indicating its broad acceptance in the healthcare market.
- Expansion Discussions Ongoing: Tonix is currently in discussions with Medicare and Medicaid to widen the coverage for Tonmya, which is expected to support future revenue growth for the company and enhance its competitive position in the pain management market.
See More
Tonix Pharmaceuticals Reports Wider Q1 Loss and Revenue Decline
- Revenue Overview: Tonix Pharmaceuticals reported a net revenue of $8.3 million for Q1 2026, with approximately $3.7 million coming from its newly launched drug Tonmya, indicating growth but significant loss pressures remain.
- Widening Loss Expectations: The company anticipates a preliminary net loss of about $40.8 million for Q1 2026, a stark increase from the $16.8 million loss reported in the same quarter of 2025, highlighting challenges in drug promotion and market acceptance.
- Strong Cash Position: As of the end of Q1, Tonix held approximately $185.5 million in cash and cash equivalents, along with $17.4 million raised in April 2026, which is expected to sustain operations until Q2 2027, ensuring continued investment in R&D and marketing.
- Market Sentiment Analysis: Despite a 25% decline in TNXP's stock over the past year, retail sentiment on Stocktwits remains bearish, although some users believe the company's early 2026 performance is misunderstood, reflecting potential confidence in future growth.
See More
TNXP Shares Plummet for Four Consecutive Days as Investors Anticipate Drug Pipeline Returns
Tonix Pharmaceuticals Updates: Tonix is evaluating its Tonmya drug for treating major depressive disorder and acute stress disorder, with plans to initiate a U.S. field study in 2027 for its experimental drug TNX-4800 aimed at seasonal prevention of Lyme disease.
Stock Performance: Shares of Tonix Pharmaceuticals (TNXP) have fallen for four consecutive days, although retail sentiment around the stock has increased by 92% in the past 24 hours, with analysts rating it a 'Buy'.
Drug Approvals and Usage: The U.S. FDA approved Tonix's Tonmya for managing fibromyalgia in adults, and over 2,500 patients have started treatment with it since its launch in November.
Future Pipeline Candidates: Tonix's pipeline includes TNX-2900 for treating Prader-Willi syndrome, TNX-1500 for preventing kidney transplant rejection, and TNX-1900 for treating migraines, with analysts suggesting a potential upside for the stock.
See More
Life Sciences Virtual Investor Forum Highlights Available On-Demand
- Forum Overview: The Life Sciences Virtual Investor Forum, held on March 11-12, showcased innovative companies from biotechnology, medical devices, and pharmaceuticals, providing investors with insights into emerging technologies and strategic growth opportunities, thereby attracting significant investor interest.
- Presentation Access: Attendees can view forum presentations on-demand for 90 days, available 24/7, which enhances investor-company interaction and improves information transparency in the investment community.
- 1x1 Meeting Requests: Select companies are accepting management meeting requests through March 17, facilitating direct communication between investors and company executives, which strengthens investor relations management.
- Enhanced Investor Engagement: Virtual Investor Conferences provide a real-time interactive platform that allows companies to connect more efficiently with investors, significantly increasing investor engagement and marking an innovation in investor communication methods.
See More
Tonix Pharmaceuticals Reports Strong Q4 Results with Nearly Doubling Sales
- Strong Sales Performance: Tonix Pharmaceuticals reported fourth-quarter sales of $5.39 million, exceeding market expectations of $2.88 million, although the company posted a loss of $3.98 per share, missing the anticipated loss of $3.16, indicating robust product demand.
- Pipeline Progress: Since its launch in November 2025, over 1,500 healthcare providers have prescribed Tonmya, with approximately 2,500 patients initiating treatment and cumulative prescriptions totaling around 4,200, reflecting increasing market acceptance.
- Robust Cash Position: As of December 31, 2025, Tonix Pharmaceuticals holds approximately $207.6 million in cash and cash equivalents, which is expected to support operations into the first quarter of 2027, enhancing financial stability.
- Market Performance Analysis: Despite a 1.12% increase in premarket trading to $13.56, Tonix's stock price remains below both the 20-day and 100-day simple moving averages, indicating a bearish trend in the short term, prompting investors to exercise caution.
See More
Tonmya Receives FDA Approval, New Option for Fibromyalgia Treatment
- FDA Approval Milestone: Tonmya has become the first FDA-approved treatment for fibromyalgia in over 15 years, representing a significant advancement in non-opioid therapies for chronic pain management, which is expected to enhance patient quality of life.
- Market Access Expansion: The new agreement with a major purchasing organization broadens Tonmya's coverage to approximately 35 million commercially insured patients in the U.S., significantly increasing the drug's market accessibility and likely driving revenue growth for the company.
- Patient Support Commitment: Tonix is dedicated to improving patient access to Tonmya by engaging with commercial payers and offering a patient support program, addressing the dissatisfaction experienced by 85% of patients with first-line treatments due to efficacy and tolerability issues, thereby enhancing patient satisfaction.
- Future Research Initiatives: Tonix is also advancing clinical trials for TNX-4800, with plans to have drug supplies ready by 2027, which is expected to provide new treatment options for Lyme disease prevention, further expanding the company's product portfolio.
See More
Tonix Pharmaceuticals Secures Coverage for Tonmya with GPO Agreement
- Agreement Reached: Tonix Pharmaceuticals has entered into an agreement with a group purchasing organization to secure commercial payer coverage for its non-opioid pain therapy, Tonmya, which is expected to cover approximately 35 million U.S. commercial lives, accounting for about one-fifth of the total U.S. commercial lives.
- Market Potential Unveiled: The agreement took effect on May 1, marking Tonix's first partnership in managed care, with CEO Seth Lederman expressing optimism about this collaboration and looking forward to expanding coverage across commercial and government channels.
- Medicare Coverage Status: Tonmya, a sublingual tablet formulation, is currently covered under Medicare in 38 states, involving nearly 55 million Medicaid members, which constitutes 73% of the approximately 75 million members of the joint federal and state healthcare plan, indicating its broad acceptance in the healthcare market.
- Expansion Discussions Ongoing: Tonix is currently in discussions with Medicare and Medicaid to widen the coverage for Tonmya, which is expected to support future revenue growth for the company and enhance its competitive position in the pain management market.
See More
Tonix Pharmaceuticals Reports Wider Q1 Loss and Revenue Decline
- Revenue Overview: Tonix Pharmaceuticals reported a net revenue of $8.3 million for Q1 2026, with approximately $3.7 million coming from its newly launched drug Tonmya, indicating growth but significant loss pressures remain.
- Widening Loss Expectations: The company anticipates a preliminary net loss of about $40.8 million for Q1 2026, a stark increase from the $16.8 million loss reported in the same quarter of 2025, highlighting challenges in drug promotion and market acceptance.
- Strong Cash Position: As of the end of Q1, Tonix held approximately $185.5 million in cash and cash equivalents, along with $17.4 million raised in April 2026, which is expected to sustain operations until Q2 2027, ensuring continued investment in R&D and marketing.
- Market Sentiment Analysis: Despite a 25% decline in TNXP's stock over the past year, retail sentiment on Stocktwits remains bearish, although some users believe the company's early 2026 performance is misunderstood, reflecting potential confidence in future growth.
See More
TNXP Shares Plummet for Four Consecutive Days as Investors Anticipate Drug Pipeline Returns
Tonix Pharmaceuticals Updates: Tonix is evaluating its Tonmya drug for treating major depressive disorder and acute stress disorder, with plans to initiate a U.S. field study in 2027 for its experimental drug TNX-4800 aimed at seasonal prevention of Lyme disease.
Stock Performance: Shares of Tonix Pharmaceuticals (TNXP) have fallen for four consecutive days, although retail sentiment around the stock has increased by 92% in the past 24 hours, with analysts rating it a 'Buy'.
Drug Approvals and Usage: The U.S. FDA approved Tonix's Tonmya for managing fibromyalgia in adults, and over 2,500 patients have started treatment with it since its launch in November.
Future Pipeline Candidates: Tonix's pipeline includes TNX-2900 for treating Prader-Willi syndrome, TNX-1500 for preventing kidney transplant rejection, and TNX-1900 for treating migraines, with analysts suggesting a potential upside for the stock.
See More
Life Sciences Virtual Investor Forum Highlights Available On-Demand
- Forum Overview: The Life Sciences Virtual Investor Forum, held on March 11-12, showcased innovative companies from biotechnology, medical devices, and pharmaceuticals, providing investors with insights into emerging technologies and strategic growth opportunities, thereby attracting significant investor interest.
- Presentation Access: Attendees can view forum presentations on-demand for 90 days, available 24/7, which enhances investor-company interaction and improves information transparency in the investment community.
- 1x1 Meeting Requests: Select companies are accepting management meeting requests through March 17, facilitating direct communication between investors and company executives, which strengthens investor relations management.
- Enhanced Investor Engagement: Virtual Investor Conferences provide a real-time interactive platform that allows companies to connect more efficiently with investors, significantly increasing investor engagement and marking an innovation in investor communication methods.
See More
Tonix Pharmaceuticals Reports Strong Q4 Results with Nearly Doubling Sales
- Strong Sales Performance: Tonix Pharmaceuticals reported fourth-quarter sales of $5.39 million, exceeding market expectations of $2.88 million, although the company posted a loss of $3.98 per share, missing the anticipated loss of $3.16, indicating robust product demand.
- Pipeline Progress: Since its launch in November 2025, over 1,500 healthcare providers have prescribed Tonmya, with approximately 2,500 patients initiating treatment and cumulative prescriptions totaling around 4,200, reflecting increasing market acceptance.
- Robust Cash Position: As of December 31, 2025, Tonix Pharmaceuticals holds approximately $207.6 million in cash and cash equivalents, which is expected to support operations into the first quarter of 2027, enhancing financial stability.
- Market Performance Analysis: Despite a 1.12% increase in premarket trading to $13.56, Tonix's stock price remains below both the 20-day and 100-day simple moving averages, indicating a bearish trend in the short term, prompting investors to exercise caution.
See More
